(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31±³À°ÀÏÀÚ : 2022-03-31
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : Çѹ®¼÷
¿¬¶ôó : 02-566-6031
À̸ÞÀÏ :
icksh@icksh.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 150,000¿ø
ºñ°í 2¿ù 28ÀϱîÁö 100,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-31 Room 1 09:00~09:20 Next generation CAR-T cell therapy against hematological malignancies ÃÖ°æÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-31 Room 1 09:20~09:40 Effective conditioning regimen in adoptive T cell therapy of cancer ÇÑÁØ¿µ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 03-31 Room 1 09:40~10:05 Tissue resident memory T cells in multiple myeloma ÃÖÀ±¼÷(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03-31 Room 1 10:05~10:30 T-cell-based immunotherapeutic strategies against EBV(Epstein-Barr virus)-positive malignancies using the novel TCR(T-Cell Receptor) specific for LMP1(latent membrane protein) antigen ±èűÔ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-31 Room 1 10:30~11:15 Immune landscape of hematological malignancies and functional screening tools Satu Mustjoki(University of Helsinki Finland)
±³À°½Ã°£ 03-31 Room 1 11:30~12:10 What is the role of C5 inhibitors in PNH(Paroxysmal nocturnal hemoglobinuria)? ±èÁø¼®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-31 Room 2 12:40~13:40 Potential prognostic significance of promoter methylation status of DNA repair genes at diagnosis in Acute myeloid leukemia: analysis of TCGA(Acute Myeloid Leukemia)-LAML(acute myeloid leukemia) cohort and patients in a single institution ¹Ú¼³Èñ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 03-31 Room 2 13:55~14:25 Recent advances in molecular diagnosis, prognosis and monitoring of MPNs(myeloproliferative neoplasm) ±è¸í½Å(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-31 Room 2 14:25~14:55 Molecular mechanisms underlying the development of MPN(myeloproliferative neoplasm) by mutant calreticulin and the therapeutic potential of an antibody targeting mutant calreticulin Norio Komatsu(Juntendo University Japan)
±³À°½Ã°£ 03-31 Room 2 14:55~15:25 Modeling improved targeting of JAK2V617F in MPNs(myeloproliferative neoplasm) Andrew J. Dunbar(Memorial Sloan Kettering Cancer Center USA)
±³À°½Ã°£ 03-31 Room 3 15:40~16:10 Immune landscapes and chemotherapy resistance in AML(cute myeloid leukemia) Sergio Rutella(Nottingham Trent University UK)
±³À°½Ã°£ 03-31 Room 3 16:10~16:40 Towards next-generation T cell engineering for cancer ±èÂùÇõ(KAIST)
±³À°½Ã°£ 03-31 Room 3 16:40~17:10 Endogenous retroviruses as a source of tumor antigens in solid tumors and acute myeloid leukemia Stéphane Depil(Université Claude Bernard Lyon France)